Advertisement ZyGEM to integrate enzymatic technology into Quanta PCR kits - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

ZyGEM to integrate enzymatic technology into Quanta PCR kits

ZyGEM has signed an agreement to integrate its enzymatic RNA extraction technology into Quanta Biosciences' kits for quantitative PCR.

The companies have kept further terms of the agreement confidential.

ZyGEM CEO Paul Kinnon said the RNA extraction technology represents an advance in sample preparation for RNA-based testing and analysis.

The reagents for quantitative PCR are used to enable applications for gene expression, pathogen detection and genetic analyses in industries such as pharmaceutical R&D, diagnostics, agribusiness and bio-defense.

ZyGEM’s enzymatic technology provides complete extraction of RNA, such as smaller RNA molecules, non-coding RNA and micro-RNA, using a single tube process.

The technology delivers higher molecular weight RNA, representative transcriptome profiles and ensures 100% reproducible results, ZyGEM said.